Nuveen LLC Buys Shares of 239,940 Immunome, Inc. $IMNM

Key Points

• Nuveen LLC has acquired 239,940 shares of Immunome, Inc., valued at approximately $1.6 million, representing about 0.28% of the company.
• Several large investors have boosted their positions in Immunome, with Vanguard Group increasing its holdings by 43.4% in the first quarter.
• Analysts have shown a favorable outlook for Immunome, with an average rating of "Buy" and a consensus target price of $22.50 for its stock.

Nuveen LLC bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 239,940 shares of the company's stock, valued at approximately $1,615,000. Nuveen LLC owned approximately 0.28% of Immunome at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IMNM. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the 4th quarter valued at about $70,000. Tower Research Capital LLC TRC boosted its stake in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Immunome during the 4th quarter valued at about $95,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Immunome during the 1st quarter valued at about $95,000. Finally, KLP Kapitalforvaltning AS boosted its stake in shares of Immunome by 140.8% during the 1st quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock valued at $115,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Wedbush reissued an "outperform" rating and set a $21.00 price target on shares of Immunome in a research report on Thursday, August 7th. Evercore ISI initiated coverage on shares of Immunome in a research report on Friday, August 22nd. They set an "outperform" rating and a $18.00 price target for the company. Guggenheim reissued a "buy" rating and set a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. Finally, Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Immunome has a consensus rating of "Buy" and a consensus price target of $22.50.

Immunome Stock Performance

Shares of IMNM traded down $0.45 during mid-day trading on Thursday, hitting $9.80. 910,944 shares of the company traded hands, compared to its average volume of 649,315. The stock has a 50-day moving average price of $9.85 and a two-hundred day moving average price of $8.85. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $16.73. The stock has a market cap of $852.99 million, a price-to-earnings ratio of -3.18 and a beta of 1.92.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. On average, analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.